Piper Sandler initiated coverage of Immunome with an Overweight rating and $27 price target. The company is developing AL-102 in Phase 3 trials as a treatment for desmoid tumors and early clinical data have reported strong efficacy, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM: